Board changes for Flamingo AI, new Chair appointed


Published 27-AUG-2018 11:52 A.M.


3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Flamingo AI Limited (ASX:FGO) has updated the market on changes to its board, including the appointment of John Murray as Non-Executive Chairman, effective 1 October 2018.

Murray has 25 years’ international experience in private equity and venture capital and was a co-founder and Managing Partner of Technology Venture Partners in 1997 — one of the original and leading venture capital firms in Australia.

He brings 12 years’ experience in executive roles in corporate banking, accounting and IT services industries, and is currently non-executive Chairman of ASX-listed PainChek Ltd, which has developed an AI-based pain assessment technology for global markets.

Murray is a past chairman of the Australian Venture Capital & Private Equity Association and has considerable experience as an investor as well as a non-executive director of technology companies with an international focus. According to FGO’s announcement, he “possesses a broad understanding of global trends in technology and their impact on a variety of industries including financial services”.

Murray is a member of the Institute of Chartered Accountants of Scotland, and the Australian Institute of Company Directors, and also has an Honours degree in Law from Edinburgh University.

The company has agreed to issue four million Class H Performance Rights and four million Class I Performance Rights to Murray as part of his negotiated package and to align his interests with shareholders.

Resignation of Bryn Hardcastle

FGO has also informed the market that Bryn Hardcastle resigned from the board due to other work commitments, effective immediately.

Hardcastle was a Non-Executive Director of FGO since it re-listed on the ASX in November 2016 and acting Chairperson since 1 July 2018.

The company stated that Hardcastle has been instrumental to its early stage growth and development.

FGO CEO & Founder, Dr Catriona Wallace commented on the news: “We are extremely pleased with the appointment of Mr Murray to the Chair role. John brings an enormous amount of experience in both the capital markets and growing technology companies globally. I very much look forward to working closely with John to lead the company through its next growth phases.”

Dr Wallace also noted, “Mr Hardcastle has greatly contributed to the success of the Company to-date. Bryn’s guidance and advice has been invaluable to the Company. We wish Bryn the very best.”

It should be noted however that this remains a speculative stock and investors should seek professional financial advice if considering this stock for your portfolio.

In July, the company provided a comprehensive business update, stating that it was well funded to deliver against its current goals and “remains highly confident in being able to deliver significant value to its clients, their end customers and investors”.

Across the US, Australia and Asia, the small cap reporting having 10 clients progressing through paid trials or software and services contracts.

The current focus for FGO is predominantly on large insurance enterprises, with its sights set on three Fortune 100 firms in the US.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free